Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Abroad (travel likely)RecruitingPHASE2

Conditions

Barrett Esophagus · Clinical Stage I Esophageal Adenocarcinoma AJCC v8 · Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 · Esophageal Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of Kansas Cancer Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Ajay Bansal) · abansal@kumc.edu · 816-861-4700
    Contact: Principal Investigator (Ajay Bansal)
  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

    Contact: Study coordinator (David Wang) · davhwang@med.umich.edu · 734-232-4594
    Contact: Principal Investigator (David Wang)
  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Paul E. Wise) · wisepe@wustl.edu · 314-454-7177
    Contact: Principal Investigator (Paul E. Wise)
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

    Contact: Study coordinator (Nicholas J. Shaheen) · nshaheen@med.unc.edu · 919-966-7047
    Contact: Principal Investigator (Nicholas J. Shaheen)
  • Case Western Reserve University, Cleveland, Ohio, United States

    Contact: Study coordinator (Amitabh Chak) · Amitabh.chak@uhhospitals.org · 216-286-0151
    Contact: Principal Investigator (Amitabh Chak)
  • Baylor University Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Vani Konda) · vani.konda@bswhealth.org · 469-800-7050
    Contact: Principal Investigator (Vani Konda)
Study leads
  • Ajay Bansal, MD

    Principal Investigator

    University of Kansas Medical Center